title: [Acute osteomyelitis in the child with sickle cell disease in a tropical zone: value of oral fluoroquinolones].
abstract: OBJECTIVE
  This study was designed to assess the efficacy and the safety of fluoroquinolones in their compassionate use for acute osteomyelitis in children with sickle cell disease in a tropical country.
  
  
  METHODS
  This study was non comparative, including twelve children (eight SS, three SC and one SEzerothalassemia) treated for acute osteomyelitis with oral ciprofloxacin or ofloxacin because of the following reasons: financial inability to afford conventional parenteral beta-lactams therapy (nine patients), refusal of hospitalization (two patients), and failure of conventional treatment (one patient).
  
  
  RESULTS
  The mean age of patients was 9.5 +/- 2.6 years. The long bones were the predominantly site. Salmonella species were present in 75% of cases, followed by other enterobacteriaceae (16.7%), and Staphylococcus aureus (8.3%). Successful outcome occurred in all cases after three to four-weeks of treatment and 45 days of plaster immobilization. Transient bilateral Achilles tendon tendinitis was noted in a five-year-old patient.
  
  
  CONCLUSIONS
  In economically developing countries, oral fluoroquinolones may be a therapeutic alternative for acute osteomyelitis in patients with sickle cell disease particularly in cases of financial hardship or failure with conventional therapy.
authors.affiliation: Unité d'infectiologie et d'oncohématologie, département de pédiatrie, université du Bénin, BP 8881, Lomé, Togo. adgbadoe@tg.refer.org
authors.forename: A D
authors.initials: AD
authors.lastname: Gbadoé
authors.forename: A
authors.initials: A
authors.lastname: Dogba
authors.forename: A Y
authors.initials: AY
authors.lastname: Dagnra
authors.forename: Y
authors.initials: Y
authors.lastname: Atakouma
authors.forename: H
authors.initials: H
authors.lastname: Tékou
authors.forename: J K
authors.initials: JK
authors.lastname: Assimadi
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000755:Anemia, Sickle Cell / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001424:Bacterial Infections / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002648:Child; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D010019:Osteomyelitis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011859:Radiography; D012189:Retrospective Studies; D012480:Salmonella Infections / Q000188:drug therapy; D014037:Togo; D014329:Tropical Climate
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones